OrbusNeich Announces Favorable Ruling from the European Patent Office and Initiation of Litigation Against Terumo Corporation

Hong Kong And Ft Lauderdale, Florida (ots/PRNewswire) -

OrbusNeich Medical, Inc. ("OrbusNeich"), a designer, developer,
manufacturer and marketer of innovative medical devices for the
treatment of vascular diseases, announced today that on May 13, 2015,
it prevailed in a final opposition appeal hearing in the European
Patent Office ("EPO") regarding European Patent EP 1 341 482 - STENT
HAVING HELICAL ELEMENTS ('482). The '482 patent has withstood the
highest level of review in the EPO and has been upheld as a valid
patent in amended form.

In a related matter, OrbusNeich announced that it had filed suit
in Germany in the District Court Duesseldorf and in the Netherlands
regarding patent infringement of the '482 patent by Terumo and their
Ultimaster[TM] Drug Eluting Stent. A request for a preliminary
injunction banning distribution of the Ultimaster Drug Eluting Stent
has been filed in Germany.

"Our intellectual property represents the creativity of OrbusNeich
employees. We have spent considerable resources creating our IP
portfolio which is one of the base assets of companies operating in
this industry. We don't view ourselves as a particularly litigious
company, but as we have demonstrated in the past, we will vigorously
defend our intellectual property." said Wayne Johnson, President and
Chief Executive Officer of OrbusNeich.

About OrbusNeich - Pioneers in life-changing technologies

OrbusNeich is a global pioneer in the provision of life-changing
vascular solutions and offers an extensive portfolio of products that
set industry benchmarks in vascular intervention. Current products
are the world's first dual therapy stent, the COMBO Dual Therapy
Stent, and the world's first pro-healing stent, the Genous(TM) Stent.
Other products include stents and balloons marketed under the names
of Azule(TM), R Stent(TM), Scoreflex(TM), Sapphire(TM) II,
Sapphire(TM) II Pro and Sapphire(TM) II NC. OrbusNeich is
headquartered in Hong Kong and has operations in Shenzhen, China;
Fort Lauderdale, Florida, USA.; Hoevelaken, The Netherlands; and
Tokyo, Japan. OrbusNeich supplies medical devices to interventional
cardiologists in more than 60 countries. For more information, visit
http://www.OrbusNeich.com.

Learn more about our life-changing technologies on our social
media channels:

Twitter: http://www.twitter.com/OrbusNeich

LinkedIn: http://www.linkedin.com/company/orbusneich-medical

YouTube: http://www.youtube.com/user/OrbusNeichMedia

ots Originaltext: OrbusNeich Medical, Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Contact: Keith Hummel, +1(212)474-1772, KHummel@cravath.com